Suchergebnisse - "Gupta, Neeraj"

PubPharm (23)

1

Response-Based Dosing for Ponatinib : Model-Based Analyses of the Dose-Ranging OPTIC Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Hanley, M. | Diderichsen, P. | Rich, B. | +5

2

A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Kim, R. | Leal, A. | Parikh, A. | +9

ErratumIn: Cancer Chemother Pharmacol. 2023 Mar 26;:. - PMID 36967405

3

Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

enthalten in: Journal of clinical pharmacology | 2023

von Li, C. | Watson, K. | Wang, S. | +2

4

Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors

enthalten in: Clinical pharmacology in drug development | 2022

von Zhou, X. | Diderichsen, P. | Gupta, N.

5

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development

enthalten in: Journal of clinical pharmacology | 2022

von Hanley, M. | Diderichsen, P. | Narasimhan, N. | +3

6

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

enthalten in: Journal of clinical pharmacology | 2022

von Zhou, X. | Ouerdani, A. | Diderichsen, P. | +1

7

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

enthalten in: Targeted oncology | 2022

von Shimizu, T. | Kuboki, Y. | Lin, C. | +7

ErratumIn: Target Oncol. 2022 Apr 12;:. - PMID 35412171

8

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer : Second Interim Analysis of the Phase III ALTA-1L Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Camidge, D. | Kim, H. | Ahn, M. | +19

CommentIn: J Clin Oncol. 2020 Nov 1;38(31):3581-3583. - PMID 32897826

9

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

10

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Dimopoulos, M. | Gay, F. | Schjesvold, F. | +124

CommentIn: Lancet. 2019 Jan 19;393(10168):204-205. - PMID 30545778